longevityreview.com


Seragon Biosciences administers SRN-901 orally to middle-aged mice, achieving a 34.4% extension of remaining lifespan and improved physical endurance. The compound integrates mTOR inhibition, autophagy activation, NAD+ enhancement, and senolytic stimulation to restore youthful gene expression and metabolic profiles, offering a promising approach to mitigate age-related decline and extend disease-free lifespan.

Key points

  • Oral SRN-901 extends remaining lifespan by 34.4% and more than doubles endurance in middle-aged mice.
  • Drug combines mTOR inhibition, autophagy activation, NAD+ enhancement, and senolytic stimulation to restore youthful gene expression.
  • Multi-omics profiling and machine learning bioinformatics reveal pathway modulation, improved metabolic markers, and reduced senescence.

Why it matters: This study demonstrates a multi-targeted drug that robustly extends lifespan and healthspan, paving the way for next-generation longevity therapies.

Q&A

  • What is mTOR?
  • How does SRN-901 differ from rapamycin?
  • What does healthspan mean?
  • How does machine learning assist in this study?
Copy link
Facebook X LinkedIn WhatsApp
Share post via...

Facing a surge in life expectancy, we need treatments that boost healthspan alongside lifespan. Seragon’s SRN-901, acting on mTOR, autophagy, NAD+ and senolytic pathways, delivered a 34.4% lifespan extension in over 300 middle-aged mice. Treated groups ran twice as far on treadmills and showed youthful gene expression, suggesting a breakthrough in comprehensive aging interventions.

Key points

  • SRN-901 extended remaining lifespan by 34.4% in middle-aged mice and improved physical endurance.
  • Treatment restored youthful gene expression in key longevity genes (Sirt6, Parp1, Sod2) and reduced anti-longevity markers.
  • Integrated bioinformatics analysis showed enhancements in metabolic and immune function pathways, suggesting significant healthspan benefits.

Q&A

  • What is SRN-901?
  • How does SRN-901 outperform rapamycin?
  • What is the difference between lifespan and healthspan?
  • Which pathways does SRN-901 target?
Copy link
Facebook X LinkedIn WhatsApp
Share post via...

In a recent preclinical study, Seragon Biosciences’ SRN-901 extended the remaining lifespan of middle-aged mice by approximately 34%. Led by Senior Scientist David Brown, the study demonstrated improved physical endurance and gene expression resembling youthful profiles. These findings offer promising evidence for potential anti-aging therapies and innovative prospects in biomedical longevity research.

Q&A

  • What is SRN-901?
  • How effective was the treatment?
  • What methodologies were used in the study?
Copy link
Facebook X LinkedIn WhatsApp
Share post via...

A recent study by Seragon Biosciences presents SRN-901 as a promising anti-aging intervention. In middle-aged mice, the drug extended remaining lifespan by 34.4% and boosted endurance and cognitive function. Dr. David Brown’s findings, backed by machine learning bioinformatics, offer actionable insights for enhancing healthspan. Reviewing these results may guide future therapeutic strategies.

Copy link
Facebook X LinkedIn WhatsApp
Share post via...